China Pharma Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CPHI research report →
Companywww.chinapharmaholdings.com
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.
- CEO
- Zhilin Li
- IPO
- 2002
- Employees
- 224
- HQ
- Haikou, CN
Price Chart
Valuation
- Market Cap
- $2.26M
- P/E
- -5.13
- P/S
- 0.57
- P/B
- 0.49
- EV/EBITDA
- -4.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -13.42%
- Op Margin
- -90.13%
- Net Margin
- -88.82%
- ROE
- -0.00%
- ROIC
- -8.66%
Growth & Income
- Revenue
- $4.14M · -8.49%
- Net Income
- $-3,187,556 · 32.70%
- EPS
- $-0.74 · -174.07%
- Op Income
- $-3,088,540
- FCF YoY
- 101.45%
Performance & Tape
- 52W High
- $2.60
- 52W Low
- $0.38
- 50D MA
- $0.64
- 200D MA
- $1.23
- Beta
- 1.00
- Avg Volume
- 282.02K
Get TickerSpark's AI analysis on CPHI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 28, 23 | Liu Tao (Chengdu) | other | 0 |
| Sep 29, 23 | Li Zhilin | other | 13,757,063 |
| Dec 30, 22 | Deng Ke | other | 0 |
| Sep 9, 21 | Li Zhilin | other | 1,760,000 |
| Dec 23, 20 | Li Zhilin | other | 2,000,000 |
| Apr 28, 12 | WAUNG FRANK | other | 100,000 |
| May 25, 11 | WAUNG FRANK | sell | 25,000 |
| Apr 28, 10 | WAUNG FRANK | sell | 150,000 |
| Oct 13, 09 | WAUNG FRANK | sell | 10,000 |
| May 25, 11 | Li Zhilin | other | 50,000 |
Our CPHI Coverage
We haven't published any research on CPHI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CPHI Report →